Robert L Coffman
Overview
Explore the profile of Robert L Coffman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
6539
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ribas A, Medina T, Kummar S, Amin A, Kalbasi A, Drabick J, et al.
Cancer Discov
. 2018 Aug;
8(10):1250-1257.
PMID: 30154193
PD-1 inhibitors are approved for treating advanced melanoma, but resistance has been observed. This phase Ib trial evaluated intratumoral SD-101, a synthetic CpG oligonucleotide that stimulates Toll-like receptor 9 (TLR9),...
12.
Frank M, Reagan P, Bartlett N, Gordon L, Friedberg J, Czerwinski D, et al.
Cancer Discov
. 2018 Aug;
8(10):1258-1269.
PMID: 30154192
This multicenter phase I/II clinical trial evaluated intratumoral SD-101, a TLR9 agonist, and low-dose radiation in patients with untreated indolent lymphoma. Twenty-nine enrolled patients received 4 Gy of radiation followed...
13.
Gallotta M, Assi H, Degagne E, Kannan S, Coffman R, Guiducci C
Cancer Res
. 2018 Jun;
78(17):4943-4956.
PMID: 29945961
Currently approved inhibitors of the PD-1/PD-L1 pathway represent a major advance for the treatment of lung cancers, yet they are ineffective in a majority of patients due to lack of...
14.
Jackson S, Candia A, Delaney S, Floettmann S, Wong C, Campbell J, et al.
Clin Pharmacol Ther
. 2017 Nov;
104(2):335-345.
PMID: 29134633
Current asthma treatments address symptoms rather than the underlying disease pathophysiology, a better understanding of which has led to the identification of the Th2 high endotype. The activation of Toll-like...
15.
Sato-Kaneko F, Yao S, Ahmadi A, Zhang S, Hosoya T, Kaneda M, et al.
JCI Insight
. 2017 Sep;
2(18).
PMID: 28931759
Checkpoint inhibitors have demonstrated efficacy in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). However, the majority of patients do not benefit from these agents. To...
16.
Wang S, Campos J, Gallotta M, Gong M, Crain C, Naik E, et al.
Proc Natl Acad Sci U S A
. 2016 Nov;
113(46):E7240-E7249.
PMID: 27799536
Despite the impressive rates of clinical response to programmed death 1 (PD-1) blockade in multiple cancers, the majority of patients still fail to respond to this therapy. The CT26 tumor...
17.
Milley B, Kiwan R, Ott G, Calacsan C, Kachura M, Campbell J, et al.
Bioconjug Chem
. 2016 Apr;
27(5):1293-304.
PMID: 27074387
We have synthesized and characterized a novel phosphorothioate CpG oligodeoxynucleotide (CpG ODN)-Ficoll conjugated nanoparticulate adjuvant, termed DV230-Ficoll. This adjuvant was constructed from an amine-functionalized-Ficoll, a heterobifunctional linker (succinimidyl-[(N-maleimidopropionamido)-hexaethylene glycol] ester)...
18.
Kachura M, Hickle C, Kell S, Sathe A, Calacsan C, Kiwan R, et al.
J Immunol
. 2015 Nov;
196(1):284-97.
PMID: 26608924
Nanoparticulate delivery systems for vaccine adjuvants, designed to enhance targeting of secondary lymphoid organs and activation of APCs, have shown substantial promise for enhanced immunopotentiation. We investigated the adjuvant activity...
19.
Jacquemin C, Schmitt N, Contin-Bordes C, Liu Y, Narayanan P, Seneschal J, et al.
Immunity
. 2015 Jun;
42(6):1159-70.
PMID: 26070486
Increased activity of T follicular helper (Tfh) cells plays a major pathogenic role in systemic lupus erythematosus (SLE). However, the mechanisms that cause aberrant Tfh cell responses in SLE remain...
20.
Campbell J, Kell S, Kozy H, Lum J, Sweetwood R, Chu M, et al.
Thorax
. 2014 Jan;
69(6):565-573.
PMID: 24464743
Background: CpG-containing oligodeoxynucleotides (CpG-ODNs) are potent inhibitors of T helper 2 mediated allergic airway disease in sensitised mice challenged with allergen. A single treatment has transient effects but a limited...